Samsung Biologics
1.354.000,00 ₩Variación respecto al cierre anterior: −4,61 %Variación absoluta: −65.363,63 ₩
En resumen
- Crecimiento de los ingresos
- +30,31 %
- 2025 frente a 2024
- Crecimiento del beneficio neto
- +64,71 %
- 2025 frente a 2024
- Margen neto
- 39,2 %
- 2024: 31,0 %
Datos financieros
Importes en millones de KRW; valores por acción en KRW; acciones en millones.
| Partida | T2 2026 | T1 2026 | T4 2025 | T3 2025 | T2 2025 | T1 2025 | T4 2024 | T3 2024 | T2 2024 | T1 2024 | T4 2023 | T3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | 1.320.911 | 1.257.119 | 1.286.000 | 1.660.221 | 1.014.238 | 999.545 | — | 1.187.075 | 1.156.904 | 946.903 | 1.073.509 | 1.033.973 |
| Coste de ventas | 622.579 | 578.274 | 614.000 | 685.412 | 450.791 | 461.152 | — | 646.205 | 501.783 | 528.557 | 544.989 | 534.019 |
| Beneficio bruto | 698.332 | 678.846 | 672.000 | 974.808 | 563.446 | 538.392 | — | 540.870 | 655.121 | 418.346 | 528.520 | 499.955 |
| Gastos generales, de venta y administración | 87.897 | 81.679 | 144.000 | 198.012 | 69.212 | 88.051 | — | 163.336 | 172.493 | 160.930 | 133.951 | 140.226 |
| Investigación y desarrollo | 9.032 | 7.238 | -72.698 | 34.281 | 8.634 | 7.582 | — | 29.617 | 26.581 | 24.575 | 22.402 | 21.115 |
| Resultado operativo | 586.444 | 580.753 | 528.000 | 728.848 | 477.202 | 430.240 | — | 338.578 | 434.511 | 221.299 | 349.968 | 318.531 |
| EBIT | 586.444 | 580.753 | 528.000 | 728.848 | 477.202 | 430.240 | — | 338.578 | 434.511 | 221.299 | 349.968 | 318.531 |
| EBITDA | 698.522 | 675.311 | 556.741 | 907.768 | 655.399 | 593.640 | — | 495.400 | 582.557 | 364.716 | 491.913 | 457.056 |
| Gastos financieros | 8.776 | 7.146 | 285 | 10.707 | 5.157 | 7.394 | — | 1.725 | 8.175 | 16.087 | 19.470 | 21.640 |
| Beneficio antes de impuestos | 584.629 | 640.593 | 575.000 | 767.004 | 442.365 | 439.102 | — | 290.999 | 464.960 | 240.077 | 355.712 | 316.313 |
| Impuestos | 153.975 | 171.348 | 122.000 | 192.544 | 108.796 | 107.769 | — | 26.531 | 146.968 | 60.715 | 65.028 | 75.946 |
| Beneficio neto | 430.654 | 469.245 | 510.000 | 574.460 | 324.386 | 375.554 | — | 264.468 | 317.992 | 179.362 | 290.684 | 240.367 |
| Beneficio neto para accionistas ordinarios | 430.654 | 469.245 | 510.000 | 574.460 | 324.386 | 375.554 | — | 264.468 | 317.992 | 179.362 | 290.684 | 240.367 |
| BPA básico | 9.313,55 | 10.148,15 | 14.382,79 | 12.409,76 | 7.007,55 | 8.112,89 | — | 5.713,18 | 6.869,42 | 3.874,66 | 6.279,49 | 5.192,52 |
| BPA diluido | 9.313,55 | 10.148,00 | 14.382,79 | 12.409,45 | 7.007,55 | 8.112,50 | — | 5.713,18 | 6.869,42 | 3.874,59 | 6.279,30 | 5.192,26 |
| Acciones medias (básicas) | 46,2 | 46,2 | 35,5 | 46,3 | 46,3 | 46,3 | — | 46,3 | 46,3 | 46,3 | 46,3 | 46,3 |
| Acciones medias (diluidas) | 46,2 | 46,2 | 35,5 | 46,3 | 46,3 | 46,3 | — | 46,3 | 46,3 | 46,3 | 46,3 | 46,3 |